Xvivo Perfusion AB
STO:XVIVO

Watchlist Manager
Xvivo Perfusion AB Logo
Xvivo Perfusion AB
STO:XVIVO
Watchlist
Price: 467 SEK 3.09% Market Closed
Market Cap: 14.7B SEK
Have any thoughts about
Xvivo Perfusion AB?
Write Note

Xvivo Perfusion AB
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Xvivo Perfusion AB
Cash & Cash Equivalents Peer Comparison

Comparables:
O
OSSD
D
DOXA
BACTI B
V
VIMIAN
S
S2M

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Xvivo Perfusion AB
STO:XVIVO
Cash & Cash Equivalents
kr450m
CAGR 3-Years
17%
CAGR 5-Years
18%
CAGR 10-Years
23%
O
OssDsign AB
STO:OSSD
Cash & Cash Equivalents
kr165.9m
CAGR 3-Years
50%
CAGR 5-Years
64%
CAGR 10-Years
N/A
D
Doxa AB
STO:DOXA
Cash & Cash Equivalents
kr11.8m
CAGR 3-Years
121%
CAGR 5-Years
3%
CAGR 10-Years
10%
Bactiguard Holding AB
STO:BACTI B
Cash & Cash Equivalents
kr123.2m
CAGR 3-Years
132%
CAGR 5-Years
131%
CAGR 10-Years
N/A
V
Vimian Group AB
STO:VIMIAN
Cash & Cash Equivalents
€41.2m
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
S2Medical AB (publ)
STO:S2M
Cash & Cash Equivalents
kr1.4m
CAGR 3-Years
-48%
CAGR 5-Years
-45%
CAGR 10-Years
N/A

See Also

What is Xvivo Perfusion AB's Cash & Cash Equivalents?
Cash & Cash Equivalents
450m SEK

Based on the financial report for Sep 30, 2024, Xvivo Perfusion AB's Cash & Cash Equivalents amounts to 450m SEK.

What is Xvivo Perfusion AB's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
23%

Over the last year, the Cash & Cash Equivalents growth was -24%. The average annual Cash & Cash Equivalents growth rates for Xvivo Perfusion AB have been 17% over the past three years , 18% over the past five years , and 23% over the past ten years .

Back to Top